Toppublicaties

Melanoom

Geselecteerd door: Melanoom
  • juni 2023

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

  • Khattak A, Weber J S, Meniawy T, et al.

Pembrolizumab voor én na operatie geeft eventvrij overlevingsvoordeel melanoom
  • maart 2023

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

  • Patel S P, Othus M, Chen Y, et al.
  • januari 2023

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

  • Chesney J A, Ribas A, Long G V, et al.
  • november 2022

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

  • Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas
  • oktober 2022

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

  • Olivier J van Not, Rik J Verheijden, Alfonsus J M van den Eertwegh
  • oktober 2022

Neoadjuvant relatlimab and nivolumab in resectable melanoma

  • Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton
  • oktober 2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

  • Georgina V Long, Jason J Luke, Muhammad A Khattak
  • september 2022

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

  • Atkins MB, Lee SJ, Chmielowski B, et al.
  • september 2022

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

  • Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
  • september 2022

LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

  • S. Patel, M. Othus, V. Prieto, et al.
Duiding door Dr. Sofie Wilgenhof

Tumor-infiltrerende lymfocyten effectief bij vergevorderd melanoom
  • september 2022

LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

  • J.B.A.G. Haanen, M. Rohaan, T.H. Borch, et al.

Immuuntherapie gevolgd door BRAF-remmers geeft mogelijk overlevingsvoordeel
  • september 2022

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

  • Ascierto PA, Mandalà M, Ferrucci PF, et al.
Gedownload van https://medischeoncologie.nl/ op 21-09-2023 om 20:07. Copyright (C) 2023 BPM Medica.

Deel deze pagina